LIGAND PHARMACEUTICALS INCORPORATED Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of -$39.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2026-06-30 was -$39.31M.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2021-09-30 was -$32.00K.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2021-06-30 was -$1.07M.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2021-03-31 was -$11.12M.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for fiscal 2021 was -$12.41M.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for fiscal 2020 was -$3.24M.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for fiscal 2018 was $18.86M, a 76.19% increase from fiscal 2017.
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, equity component of convertible debt for fiscal 2017 was $10.70M, a 6.35% increase from fiscal 2016.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month as first filed | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$39.31M 10-Q · filed 2026-08-07 | ||||
| 2021-12-31 | -$12.41M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | -$32.00K 10-Q · filed 2021-11-09 | -$1.10M derived: sum of 2 quarters · filed 2021-11-09 | -$12.22M derived: sum of 3 quarters · filed 2022-08-09 | ||
| 2021-06-30 | -$1.07M 10-Q · filed 2021-11-09 | -$12.19M derived: sum of 2 quarters · filed 2022-08-09 | |||
| 2021-03-31 | -$11.12M 10-Q · filed 2022-08-09 | -$9.09M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | -$3.24M 10-K · filed 2023-02-28 | ||||
| 2020-06-30 | -$23.00K 10-Q · filed 2020-11-06 | -$2.77M derived: sum of 2 quarters · filed 2021-11-09 | |||
| 2020-03-31 | -$2.75M 10-Q · filed 2021-11-09 | ||||
| 2018-12-31 | $18.86M 10-K · filed 2020-02-27 | ||||
| 2018-06-30 | $16.08M 10-Q · filed 2019-11-08 | $18.86M derived: sum of 2 quarters · filed 2019-11-08 | |||
| 2018-03-31 | $2.78M 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | $10.70M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $10.06M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | -$39.63M 10-K · filed 2018-03-01 | ||||
| 2014-12-31 | $51.27M 10-K · filed 2017-02-28 |